Autoimmune etiology of generalized vitiligo

Current Directions in Autoimmunity

Volumn 10, Issue , 2008, Pages 227-243

  Le Poole, I C ^a,c   Luiten, R M ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; DOPACHROME ISOMERASE; HLA DR ANTIGEN; ISOMERASE; MART1 ANTIGEN; MELANIN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; OXIDOREDUCTASE; TUMOR ANTIGEN; TUMOR PROTEIN; TYROSINASE RELATED PROTEIN; TYROSINASE-RELATED PROTEIN;

ANIMAL; ANTIGEN PRESENTATION; AUTOIMMUNITY; ENZYMOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MELANOSOME; PATHOLOGY; PIGMENTATION; REVIEW; T LYMPHOCYTE; VITILIGO;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; AUTOIMMUNITY; CLONAL DELETION; HLA-DR ANTIGENS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MELANINS; MELANOSOMES; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; OXIDOREDUCTASES; PIGMENTATION; T-LYMPHOCYTES; VITILIGO;

EID: 38349019277     PISSN: 14222132     EISSN: 16622936     Source Type: Book Series    
DOI: 10.1159/000131485     Document Type: Review

References (70)

1. Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S, Costin G, Das P: Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm Venereol 2006;86:209-214.
2. Mason CP, Gawkrodger DJ: Vitiligo presentation in adults. Clin Exp Dermatol 2005;30:344-345.
3. Agarwal G: Vitiligo: an under-estimated problem. Fam Pract 1998;15(suppl 1):S19-S23.
4. Dogra S, Parsad D, Handa S, Kanwar AJ: Late onset vitiligo: a study of 182 patients. Int J Dermatol 2005;44:193-196.
5. Hann SK, Lee HJ: Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996;35:671-674.
6. Ongenae K, van Geel N, Naeyaert JM: Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003;16:90-100.
7. Hartmann A, Brocker EB, Becker JC: Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004;64:89-107.
8. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, Kaloumenou E, Chrousos GP: Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005;53:220-223.
9. Harning R, Cui J, Bystryn JC: Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991;97:1078-1080.
10. Gottumukkala RV, Gavalas NG, Akhtar S, Metcalfe RA, Gawkrodger DJ, Haycock JW, Watson PF, Weetman AP, Kemp EH: Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Lab Invest 2006;86:781-789.
11. van den Wijngaard RM, Asghar SS, Pijnenborg AC, Tigges AJ, Westerhof W, Das PK: Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo. Br J Dermatol 2002;146:80-87.
12. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK: Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996;148:1219-1228.
13. van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P: Local immune response in skin of generalized vitiligo patients: destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000;80:1299-1309.
14. Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C: HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 2001;116:891-897.
15. Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA: Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003;121:550-556.
16. Ogg GS, Rod DP, Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208.
17. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C: Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001;117:326-332.
18. Wang X, Erf GF: Melanocyte-specific cell mediated immune response in vitiliginous Smyth line chickens. J Autoimmun 2003;21:149-160.
19. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 2000;23:17-27.
20. Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-1055.
21. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P: Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994;38:411-416.
22. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB: Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-696.
23. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718.
24. Becker JC, Guldberg P, Zeuthen J, Brocker EB, Straten PT: Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999;113:1033-1038.
25. Kiniwa Y, Fujita T, Akada M, Ito K, Shofuda T, Suzuki Y, Yamamoto A, Saida T, Kawakami Y: Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. Cancer Res 2001;61:7900-7907.
26. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG: Direct evidence to support the role of antigen-specific CD8+ T cells in melanoma-associated vitiligo. J Invest Dermatol 2001;117:1464-1470.
27. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC: Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005;23:8978-8991.
28. Merimsky O, Shoenfeld Y, Baharav E, Zigelman R, Fishman P: Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum Antibodies Hybridomas 1996;7:151-156.
29. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
30. Jager E, Maeurer M, Hohn H, Karbach J, Jager D, Zidianakis Z, Bakhshandeh-Bath A, Orth J, Neukirch C, Necker A, Reichert TE, Knuth A: Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000;86:538-547.
31. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-8377.
32. Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG: Hypopigmentation associated with an adenovirus-mediated gp100/MART-1- transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002;138:799-802.
33. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000;192:1637-1644.
34. Au WY, Yeung CK, Chan HH, Lie AK: Generalized vitiligo after lymphocyte infusion for relapsed leukaemia. Br J Dermatol 2001;145:1015-1017.
35. Palermo B, Garbelli S, Mantovani S, Scoccia E, Da Prada GA, Bernabei P, Avanzini MA, Brazzelli V, Borroni G, Giachino C: Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur J Immunol 2005;35:3153-3162.
36. van den Boorn JG, Le Poole IC, Luiten RM: T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int Rev Immunol 2006;25:235-258.
37. Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G, Martinetti M, Benvenuto F, Merlini G, della Cuna GR, Rivoltini L, Giachino C: Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol 2003;121:308-314.
38. Cui J, Chen D, Misfeldt ML, Swinfard RW, Bystryn JC: Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995;8:60-63.
39. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW: Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002;188:136-146.
40. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-580.
41. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832.
42. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP: Vaccination with a recombinant vaccinia virus encoding a 'self ' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-2987.
43. 2 stress. J Invest Dermatol 2004;122:307-313.
44. Park B, Lee S, Kim E, Cho K, Riddell SR, Cho S, Ahn K: Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell 2006;127:369-382.
45. Tsatmali M, Ancans J, Thody AJ: Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem 2002;50:125-133.
46. Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Aubock J: Vitiligo patients present lower plasma levels of alpha-melanotropin immunoreactivities. Neuropeptides 2006;40:177-183.
47. Spencer JD, Gibbons NC, Rokos H, Peters EM, Wood JM, Schallreuter KU: Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol 2007;127:411-420.
48. Luger TA, Scholzen TE, Brzoska T, Bohm M: New insights into the functions of α-MSH and related peptides in the immune system. Ann NY Acad Sci 2003;994:133-140.
49. Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A, Gastpar R, Issels RD: Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia 2002;18:563-575.
50. Boissy RE, Manga P: On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004;17:208-214.
51. Mosher DB, Parrish JA, Fitzpatrick TB: Monobenzylether of hydroquinone: a retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol 1977;97:669-679.
52. Ivanova K, Le Poole IC, Gerzer R, Westerhof W, Das PK: Effect of nitric oxide on the adhesion of human melanocytes to extracellular matrix components. J Pathol 1997;183:469-476.
53. Iuga AO, Qureshi AA, Lerner EA: Nitric oxide is toxic to melanocytes in vitro. Pigment Cell Res 2004;17:302-306.
54. Huang CL, Nordlund JJ, Boissy R: Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002;3:301-308.
55. Swope VB, Supp AP, Schwemberger S, Babcock G, Boyce S: Increased expression of integrins and decreased apoptosis correlate with increased melanocyte retention in cultured skin substitutes. Pigment Cell Res 2006;19:424-433.
56. Kroll TM, Bommiasamy H, Boissy RE, Hernandez C, Nickoloff BJ, Mestril R, Caroline LP, I: 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 2005;124:798-806.
57. Le Poole IC, Mutis T, van den Wijngaard RM, Westerhof W, Ottenhoff T, de Vries RR, Das PK: A novel, antigen-presenting function of melanyotces and its possible relationship to hypopigmentary disorders. J Immunol 1993;151:7284-7292.
58. Kristiansen OP, Larsen ZM, Pociot F: CTLA-4 in autoimmune diseases: a general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-184.
59. Chakraborty AK, Sousa JF, Chakraborty D, Funasaka Y, Bhattacharya M, Chatterjee A, Pawelek J: GnT-V expression and metastatic phenotypes in macrophage-melanoma fusion hybrids is down-regulated by 5-Aza-dC: evidence for methylation sensitive, extragenic regulation of GnT-V transcription. Gene 2006;374:166-173.
60. high macrophages is associated with skin tumour regression. Int J Cancer 2003;106:736-744.
61. Kao CH, Yu HS: Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo. J Dermatol 1990;17:287-296.
62. Le Poole IC, Stennett LS, Bonish BK, Dee L, Robinson JK, Hernandez C, Hann SK, Nickoloff BJ: Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin. Br J Dermatol 2003;149:739-748.
63. Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK: Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003;83:683-695.
64. Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerottini JC, Romero P: Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 2002;23:325-328.
65. Collins SM, Dominguez M, Ilmarinen T, Costigan C, Irvine AD: Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy syndrome. Br J Dermatol 2006;154:1088-1093.
66. Coutinho A, Caramalho I, Seixas E, Demengeot J: Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection. Curr Top Microbiol Immunol 2005;293:43-71.
67. Matzinger P: The danger model: a renewed sense of self. Science 2002;296:301-305.
68. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-782.
69. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
70. Pianigiani E, Risulo M, Andreassi A, Taddeucci P, Ierardi F, Andreassi L: Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo. Dermatol Surg 2005;31:155-159.